FDA Sarclisa Approval Marks Sanofi's Reentry Into Oncology

The anti-CD38 antibody will face an entrenched rival, J&J's Darzalex, for multiple myeloma.

Milestone on Road — Sanofi reached a milestone getting a new cancer drug to market • Source: Shutterstock

Sanofi's Sarclisa (isatuximab) will be the first oncology drug the big pharma has developed and launched independently since the chemotherapy Jevtana (cabazitaxel) in 2010. The launch, therefore, represents a milestone for Sanofi's attempt to revitalize its cancer portfolio.

The company announced the US Food and Drug Administration approval of Sarclisa in multiple myeloma on 2 March

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Industry Leaders Grapple With Trump’s MFN Pricing Plan

14 May 2025

• By Jessica Merrill

At the Bank of America health care conference, pharma leaders speculated on what Trump’s executive order on drug pricing could mean for US and European drug prices.